In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the...
In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer ...
The imbalance between rapidly proliferating tumor cells and inadequate and inefficient tumor vasculature leads to a decrease in oxygen levels (hypoxia and/or anoxia) in tumor tissues. Intra-tumor hypoxia profoundly affects the biological behavior of cancer cells, which become resistant to conventional therapies and acquire a more invasive and metastatic phenotype. Hypoxia is a hallmark of the malignant phenotype and a key feature of the tumor microenvironment. Hypoxia Inducible Factor 1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation....
The imbalance between rapidly proliferating tumor cells and inadequate and inefficient tumor vasculature leads to a decrease in o...
In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying targeted hormonal treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen,...
In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying targeted hormo...
Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond. Due to these factors it has been said that the cost per patient of bladder cancer, from diagnosis to death...
Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among wome...
This is a practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs. It includes coverage of basic biostatistics for the clinical trialist, and fundamental concepts in clinical pharmacology.
This is a practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs. It includes coverage of basic...
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available...
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the ...
Extensive research has uncovered a set of molecular surveillance mechanisms commonly called checkpoints which tightly monitor cell-cycle processes. Today s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular...
Extensive research has uncovered a set of molecular surveillance mechanisms commonly called checkpoints which tightly monitor cell-cycle processes....
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from ...
Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain...
Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge a...
Transforming Growth Factor-jl in Cancer Therapy, Volume I: Basicand Clinical Biology The present volume brings together a wealth of information that is fundamental to understanding the roleofTGF- in the pathogenesis, prevention, and treatment of cancer. It is not even 25 years sinceTGF- was first isolated and characterized as a dimeric pep tide from both human and bovine sources (1-3), but the entire fieldofTGF- research has grown and expanded so that it is now a central theme in all of cell biology. There is almost no tissue or organ in the mammalian body in whichTGF- does not playa central...
Transforming Growth Factor-jl in Cancer Therapy, Volume I: Basicand Clinical Biology The present volume brings together a wealth of information that i...
